Mymetics Signs Agreement to Manufacture Virosome based HER-Vaxx Cancer Immunotherapy

Epalinges, Switzerland, July 16, 2014

Mymetics (OTC BB: MYMX) announced today that it has signed an exclusive agreement with Imugene (ASX; IMU), an Australian based biopharmaceutical company, to manufacture and develop its cancer immunotherapy HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015.

Media Name Media Type Description Download
140715 Press release Mymetics - Imugene cooperation - FINAL PDF Download